In a 7-year-old patient with major depressive disorder, generalized anxiety disorder, and dementia who is taking bupropion (Wellbutrin) 150 mg daily, escitalopram (Lexapro) 5 mg at bedtime, and a Deluxe Teen supplement, should any of these medications be discontinued or dose‑adjusted, and how should they be tapered?

Urgent Medication Review Required: This Regimen is Inappropriate for a 7-Year-Old

This 7-year-old should NOT be on this medication combination—immediate psychiatric consultation is needed to reassess the entire treatment plan, verify the diagnosis of dementia (which is extraordinarily rare in children), and develop an age-appropriate medication strategy with gradual tapering under close supervision.

Critical Safety Concerns

Diagnosis Verification is Essential

• Dementia in a 7-year-old is exceptionally rare and requires immediate diagnostic clarification. Childhood dementia typically results from specific genetic, metabolic, or neurodegenerative conditions that would fundamentally alter treatment approach
• The combination of MDD, GAD, and dementia in this age group is highly unusual and warrants comprehensive neuropsychiatric evaluation before any medication changes

Current Medication Concerns

Bupropion (Wellbutrin) 150 mg daily:

• This dose is at the adult starting dose for a child weighing likely 40-60 lbs
• Bupropion lowers seizure threshold—particularly concerning if dementia has an underlying neurological cause 1
• The FDA label does not establish pediatric dosing for children under 18 years 1
• Bupropion is generally considered activating and may worsen anxiety symptoms in some pediatric patients, though recent evidence suggests it can be effective for comorbid anxiety 2, 3

Escitalopram (Lexapro) 5 mg at bedtime:

• This is a reasonable pediatric dose for anxiety/depression 4
• Escitalopram has lower drug interaction potential than other SSRIs 5
• However, combining with bupropion requires careful monitoring for serotonin syndrome risk

"Deluxe Teen" supplement:

• Without knowing the specific ingredients, this could contain substances that interact with psychiatric medications
• Many supplements contain stimulants, St. John's Wort, or other compounds that can cause dangerous interactions

Recommended Action Plan

Step 1: Immediate Psychiatric Consultation

Before making any medication changes, obtain:

• Complete diagnostic re-evaluation including neuropsychological testing
• Clarification of "dementia" diagnosis with neuroimaging if not already done
• Assessment of current symptom severity and medication response
• Review of medication history: which was started first, what was the rationale, what has been the response 6

Step 2: Medication Discontinuation Strategy

If discontinuation is warranted (after specialist consultation), the AACAP guidelines provide clear direction 6:

First medication to discontinue: Bupropion

• Rationale: When a child is on two medications for overlapping disorders (both target depression), remove the medication that was likely added adjunctively 6
• Bupropion is typically added to SSRIs for augmentation in adults 7, suggesting the Lexapro was likely first-line
• Seizure risk in a child with possible neurological condition makes bupropion particularly concerning
• Taper schedule per FDA label: Reduce from 150 mg to 75 mg (if available) or 150 mg every other day for 1-2 weeks before discontinuation 1

Second medication to discontinue: "Deluxe Teen" supplement

• Remove immediately if it contains any psychoactive ingredients
• No taper needed for most supplements

Maintain Lexapro (for now)

• SSRIs have better evidence base for pediatric anxiety and depression 5
• Escitalopram has favorable tolerability profile in adolescents 4
• However, monitor closely: SSRIs require gradual tapering to avoid discontinuation syndrome (dizziness, irritability, flu-like symptoms) 6, 5
• If eventual discontinuation is planned, taper by 2.5 mg decrements every 2-4 weeks with extended monitoring, as mood/anxiety symptoms may return weeks to months after last dose 6

Step 3: Monitoring Plan

Critical monitoring requirements 6:

• Mood and anxiety symptoms may not return for weeks to months after medication discontinuation
• Use standardized rating scales (e.g., SCARED for anxiety, CDI for depression)
• Weekly contact for first month, then biweekly for 3 months
• Educate family about warning signs: increased sadness, anxiety, irritability, sleep changes, suicidal ideation
• Black box warning: All antidepressants carry increased suicidality risk in children—close monitoring is mandatory 1

Common Pitfalls to Avoid

1. Never discontinue both medications simultaneously in a child with mood/anxiety disorders—risk of symptom relapse is too high 6

2. Do not abruptly stop SSRIs—always taper to prevent discontinuation syndrome 6, 5

3. Avoid medication changes without understanding the original treatment rationale—reviewing records and speaking with previous prescribers is essential 6

4. Do not assume the current regimen is ineffective without objective data—if symptoms are well-controlled, discontinuation may not be appropriate despite concerns about polypharmacy 6

Bottom Line

This case requires immediate specialist involvement. The diagnosis of dementia in a 7-year-old, combined with adult-dose bupropion and polypharmacy, represents a high-risk situation. If medication discontinuation proceeds, remove bupropion first (with taper), eliminate the supplement, and maintain the SSRI with close monitoring. Any changes must occur under psychiatric supervision with a comprehensive monitoring plan, as symptom return can be delayed by months 6.